148 related articles for article (PubMed ID: 34823218)
1. Curcumin by activation of adenosine A
Rukoyatkina N; Shpakova V; Bogoutdinova A; Kharazova A; Mindukshev I; Gambaryan S
Biochem Biophys Res Commun; 2022 Jan; 586():20-26. PubMed ID: 34823218
[TBL] [Abstract][Full Text] [Related]
2. The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.
Xiang B; Zhang G; Ren H; Sunkara M; Morris AJ; Gartner TK; Smyth SS; Li Z
PLoS One; 2012; 7(12):e51037. PubMed ID: 23236426
[TBL] [Abstract][Full Text] [Related]
3. The role of adenosine diphosphate mediated platelet responsiveness for the stability of platelet integrity in citrated whole blood under ex vivo conditions.
Koessler J; Schwarz M; Weber K; Etzel J; Koessler A; Boeck M; Kobsar A
PLoS One; 2017; 12(11):e0188193. PubMed ID: 29155852
[TBL] [Abstract][Full Text] [Related]
4. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.
Bijak M; Szelenberger R; Dziedzic A; Saluk-Bijak J
Molecules; 2018 Feb; 23(2):. PubMed ID: 29439388
[TBL] [Abstract][Full Text] [Related]
6. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
[TBL] [Abstract][Full Text] [Related]
7. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
[TBL] [Abstract][Full Text] [Related]
8. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
9. Platelets Express Activated P2Y
Hu L; Chang L; Zhang Y; Zhai L; Zhang S; Qi Z; Yan H; Yan Y; Luo X; Zhang S; Wang Y; Kunapuli SP; Ye H; Ding Z
Circulation; 2017 Aug; 136(9):817-833. PubMed ID: 28637879
[TBL] [Abstract][Full Text] [Related]
10. The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels.
Srinivasan S; Mir F; Huang JS; Khasawneh FT; Lam SC; Le Breton GC
J Biol Chem; 2009 Jun; 284(24):16108-16117. PubMed ID: 19346255
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.
Kirkby NS; Lundberg MH; Chan MV; Vojnovic I; Solomon AB; Emerson M; Mitchell JA; Warner TD
Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15782-7. PubMed ID: 24003163
[TBL] [Abstract][Full Text] [Related]
12. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
[TBL] [Abstract][Full Text] [Related]
14. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.
Aungraheeta R; Conibear A; Butler M; Kelly E; Nylander S; Mumford A; Mundell SJ
Blood; 2016 Dec; 128(23):2717-2728. PubMed ID: 27694321
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y
Rollini F; Franchi F; Thano E; Faz G; Park Y; Kureti M; Cho JR; Been L; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2017 Jul; 10(13):1374-1375. PubMed ID: 28683943
[No Abstract] [Full Text] [Related]
16. Deciphering of ADP-induced, phosphotyrosine-dependent signaling networks in human platelets by Src-homology 2 region (SH2)-profiling.
Schweigel H; Geiger J; Beck F; Buhs S; Gerull H; Walter U; Sickmann A; Nollau P
Proteomics; 2013 Mar; 13(6):1016-27. PubMed ID: 23322602
[TBL] [Abstract][Full Text] [Related]
17. Uridine Triphosphate Thio Analogues Inhibit Platelet P2Y
Gündüz D; Tanislav C; Sedding D; Parahuleva M; Santoso S; Troidl C; Hamm CW; Aslam M
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146050
[TBL] [Abstract][Full Text] [Related]
18. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia Modulates Platelet Purinergic Signalling Pathways.
Paterson GG; Young JM; Willson JA; Graham CJ; Dru RC; Lee EW; Torpey GS; Walmsley SR; Chan MV; Warner TD; Baillie JK; Thompson AAR
Thromb Haemost; 2020 Feb; 120(2):253-261. PubMed ID: 31858521
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.
Bagoly Z; Sarkady F; Magyar T; Kappelmayer J; Pongrácz E; Csiba L; Muszbek L
PLoS One; 2013; 8(7):e69417. PubMed ID: 23844259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]